Roche (Basel, Switzerland) will cut 780 production jobs over the next two to three years, according to a story in Wall Street Journal. These layoffs follow plant restructuring that already eliminated 1,152 jobs.
Roche (Basel, Switzerland) will cut 780 production jobs over the next two to three years, according to a story in Wall Street Journal. These layoffs follow plant restructuring that already eliminated 1,152 jobs.
According to the Journal story, Chief Financial Officer Erich Hunziker said the recent cuts involved the sale and closure of factories. The new program will run until 2011.
For the full story see the WSJ web site (subscription required) ref="https://online.wsj.com/article/SB123203531536885863.html?mod=dist_smartbrief">
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Oligonucleotide Analysis in Pharmaceutical Quality Control
January 14th 2025Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.